CD274 and breast carcinoma: The U.S. Food and Drug Administration has approved PD-L1 immunohistochemistry (IHC) as a companion diagnostic for NSCLC, gastric, or gastroesophageal junction adenocarcinoma, cervical cancer, urothelial cancer, squamous cell carcinoma of the head and neck and esophagus, and breast cancer.